Is Boston Prop BXP stock cyclical or defensive In Focus 20260427 TWO Two posts sharp 30 percent Q4 2025 EPS miss shares remain flat after earnings release Moderna Inc MRNA Counterparty Arbutus Biopharma Secures Regulatory Catalyst Amid Settled LNP Licensing Agreement